Key Highlights

  • Greenwich LifeSciences (NASDAQ:GLSI) reported a net loss of USD 15.4 million for the nine months ended September 30, 2026, up from USD 10.2 million a year earlier, or USD 1.05 per share.
  • Third-quarter Research and Development expense rose 67% to USD 5.4 million on higher clinical spending, while general and administrative expense fell 12% to USD 0.4 million.
  • Cash was USD 5.9 million at September 30, 2026, against USD 6.2 million at December 31, 2025, and the filing states substantial doubt about continuing as a going concern.
  • The company sold 379,762 shares through its at-the-market program in 2026 for net proceeds of USD 9.3 million at an average price of USD 25.36 per share.

Clinical Spending Pushes the Loss Higher

Greenwich LifeSciences (NASDAQ:GLSI) filed its Quarterly Report for the period ended September 30, 2026. The Stafford, Texas-based clinical-stage biopharmaceutical company is running the Phase III Flamingo-01 trial of GLSI-100, an immunotherapy meant to prevent breast cancer recurrence in HER2-positive patients. It has no Revenue and has not generated any since its inception in 2006. The third-quarter net loss was USD 5.8 million, or USD 0.40 per share, against USD 3.7 million, or USD 0.27 per share, a year earlier. Research and development reached USD 5.4 million, up from USD 3.3 million, which the company attributes to clinical expenses.

Nine-Month Costs Reflect an Option Grant

For the nine months, research and development expense rose 59% to USD 14.2 million from USD 9.0 million. The company cites an Options grant to employees, management and directors in addition to higher clinical costs. General and administrative expense increased 6% to USD 1.4 million on finance and corporate expenses. Interest income was USD 188,553 against USD 67,442, and the weighted average share count was 14,640,432, which put the nine-month loss at USD 1.05 per share against USD 0.76. The company is expanding Flamingo-01 into Europe and plans up to 150 sites globally. Net losses were USD 19.4 million in 2025 and USD 17.4 million in 2024, and the company expects significant losses to continue as trials and Manufacturing build-out proceed. The only large non-clinical commitment disclosed is the license for GP2 from HJF.

Thin Cash and Reliance on At-the-Market Sales

Net cash used in Operating Activities was USD 9.6 million for the nine months, compared with USD 6.7 million a year earlier, and no cash was used or generated in investing activities in either period. Cash of USD 5.9 million is supported by at-the-market sales through H. C. Wainwright, which raised gross proceeds of USD 9.6 million in 2026 and net proceeds of USD 9.3 million. Shares outstanding rose to 14,678,208 from 14,298,446 at year end, an increase of about 2.7% (calculated). The filing says additional Capital will be needed, probably from Equity or Debt sales, and that success is not assured. It reports no material obligations beyond employment and Shareholder agreements and the GP2 license.

Where Things Stand

The loss grew because the company is spending more on a late-stage trial, and the funding gap is the main risk. Greenwich LifeSciences (NASDAQ:GLSI) lost USD 15.4 million in nine months, used USD 9.6 million of operating cash and ended September with USD 5.9 million. Management's own going-concern language means the trial schedule depends on more equity sales, which dilute holders. Watch Flamingo-01 site expansion, further at-the-market issuance, the fourth-quarter cash balance and any financing announcement. The filing reports no subsequent events requiring adjustment.